Showing results (2051-2060 of 10,003) with videos related to
Sort By:
Pageof 1,001
Leukemia & Lymphoma|August 9, 2017
Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patientsHamid Bur, Kirsi-Maria Haapasaari, Taina Turpeenniemi-Hujanen, et al.Leukemia & Lymphoma|July 29, 2017
FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomesTima Davidson, Meirav Kedmi, Abraham Avigdor, et al.Leukemia & Lymphoma|July 19, 2017
Variability of performance status assessment between patients with hematologic malignancies and their physiciansAlexis D Leal, Cristine Allmer, Matthew J Maurer, et al.Leukemia & Lymphoma|July 19, 2017
PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia †Caitlin R Rausch, Bernard L Marini, Lydia L Benitez, et al.Leukemia & Lymphoma|July 19, 2017
CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabineJohn N Allan, Gail J Roboz, Gulce Askin, et al.Leukemia & Lymphoma|November 9, 2017
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trialsMichael J Burke, Meenakshi Devidas, Kelly Maloney, et al.Leukemia & Lymphoma|October 17, 2017
Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, CanadaLauren J Lee, Cynthia L Toze, Steven J T Huang, et al.Leukemia & Lymphoma|October 13, 2017
Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?Chuer Zhang, Gladstone Austin Amos BurkeLeukemia & Lymphoma|August 25, 2017
High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemiaTing Si, Ying Lu, Fenglin Li, et al.Leukemia & Lymphoma|August 26, 2017
Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignanciesSteven GrantPageof 1,001